Anders Ullén

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Adjungerad professor i klinisk onkologi vid institutionen för
onkologi-patologi från 1 juli 2021. Primär anställning: Överläkare vid
enheten bäckencancer, Tema cancer vid Karolinska Universitetssjukhuset. För
mer information, se den engelska profilsidan.

Artiklar

Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2026;61:127-130
Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer
Mesinovic D; Bobjer J; Hagberg O; Aljabery F; Gardmark T; Jahnson S; Jerlstrom T; Kjolhede H; Malmstrom P-U; Strock V; Soderkvist K; Ullen A; Holmberg L; Haggstrom C; Liedberg F
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2026;394(13):1257-1269
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
Vulsteke C; Adra N; Danchaivijitr P; Sabadash M; Rodriguez-Vida A; Zhang Z; Atduev V; Goger YE; Rausch S; Kang S-H; Loriot Y; Bedke J; Galsky MD; O'donnell PH; Von Amsberg G; Alimohamed N; Sulimka G; Gupta S; Paramonov V; Nakane K; Mihm M; Meng C; Huang CD; Ramamurthy C; Homet Moreno B; Ullen A
Article: EUROPEAN UROLOGY ONCOLOGY. 2025;8(6):1486-1495
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial
Crippa A; De Laere B; Discacciati A; Larsson B; Persson M; Johansson S; D'Hondt S; Hjalm-Eriksson M; Pettersson L; Enbla G; Ullen A; Lumen N; Karlsson CT; Sandzen J; Janes E; Ghysel C; Olsson M; Sautois B; Schatteman P; De Roock W; Van Bruwaene S; Erbiene I; Darras J; Everaert E; De Maeseneer D; Anden M; Strijbos M; Luyten D; Mortezavi A; Oldenburg J; Ost P; Lindberg J; Gronberg H; Eklun M
Article: ACTA ONCOLOGICA. 2025;64:1355-1364
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
Kheir A; Johannsdottir B; Gronn-Weiss A; Liu LL; Ullen A; Laurell A; Hakansson A; Verbiene I; Ullenhag G; Carlhed R; Svedman FC; Lindskog M; Harmenberg U
Article: FRONTIERS IN ONCOLOGY. 2025;15:1680916
Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study
Soderkvist K; Haggstrom C; Hagberg O; Aljabery F; Gardmark T; Holmberg L; Hosseini A; Jerlstrom T; Kjolhede H; Malmstrom P-U; Sherif A; Liedberg F; Ullen A
Article: EUROPEAN UROLOGY. 2025;88(4):331-338
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease
Bellmunta J; Powles T; Park SH; Voog E; Valderrama BP; Gurney H; Ullen A; Loriot Y; Sridhar SS; Tsuchiya N; Sternberg CN; Aragon-Ching JB; Petrylak DP; Duran MAC; Tyroller K; Hoffman J; Jacob N; Grivas P; Gupta S
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2025;80:33-37
Applicability of the European Association of Urology 2021 Prognostic Model for Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort
Liedberg F; Hagberg O; Beijert IJ; Aljabery F; Gardmark T; Hosseini A; Jahnson S; Jerlstrom T; Kjolhede H; Malmstrom P-U; Strock V; Soderkvist K; Ullen A; van Rhijn BWG; Holmberg L; Haggstrom C
Article: BJUI COMPASS. 2025;6(9):e70093
Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas
Liedberg F; Hagberg O; Haggstrom C; Aljabery F; Gardmark T; Jahnson S; Jerlstrom T; Strock V; Soderkvist K; Ullen A; Holmberg L; Bobjer J
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2025;43(8):467.e21-467.e29
Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab
Hjorthen G; Svedman FC; Holmsten K; Ullen A
Article: ESMO OPEN. 2025;10(8):105512
Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer
Holmsten K; De Laere B; Sjodahl G; Lindberg J; Svedman FC; Ostling P; Eriksson P; Liedberg F; Ullen A
Article: ACTA ONCOLOGICA. 2025;64:42756-622
Lower MeDiC score is associated with non-referral to multidisciplinary team meeting discussion in bladder cancer patients: a nationwide and population-based study
Wihl J; Hagberg O; Aljabery F; Gardmark T; Hosseini A; Jahnson S; Jerlstrom T; Strock V; Soderkvist K; Ullen A; Holmberg L; Haggstrom C; Liedberg F
Article: BJUI COMPASS. 2025;6(5):e70021
Risk of upper urinary tract urothelial carcinoma after primary non-muscle-invasive urinary bladder cancer: A nationwide population-based cohort study
Haggstrom C; Hagberg O; Holmberg L; Hosseini A; Jerlstrom T; Strock V; Soderkvist K; Ullen A; Liedberg F; Jahnson S; Aljabery F
Article: FRONTIERS IN ONCOLOGY. 2025;15:1556881
Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting
Saha S; Gerdtham U-G; Sjodahl G; Haggstrom C; Catto JWF; Kelly JD; Ullen A; Holmberg L; Liedberg F
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2025;60:76-82
Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease
Ullen A; Aljabery F; Dahlman P; Falkman K; Gardmark T; Jerlstrom T; Holst S; Kjellstrom S; Lind A-K; Papantoniou D; Stenlund J; Strock V; Soderkvist K; Thulin H; Tragardh E; Verbiene I; Wallstrom J; Ofverholm E; Liedberg F
Article: EUROPEAN UROLOGY ONCOLOGY. 2025;8(1):119-125
Treatment Related to Urinary Tract Infections Is Associated with Delayed Diagnosis of Urinary Bladder Cancer: A Nationwide Population-based Study
Liedberg F; Gardmark T; Hagberg O; Aljabery F; Strock V; Hosseini A; Malmstrom P-U; Soderkvist K; Ullen A; Jerlstrom T; Jahnson S; Holmberg L; Haggstrom C
Article: NATURE MEDICINE. 2024;30(11):3291-3302
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
De Laere B; Crippa A; Discacciati A; Larsson B; Persson M; Johansson S; D'hondt S; Bergstrom R; Chellappa V; Mayrhofer M; Banijamali M; Kotsalaynen A; Schelstraete C; Vanwelkenhuyzen JP; Hjalm-Eriksson M; Pettersson L; Ullen A; Lumen N; Enblad G; Thellenberg Karlsson C; Janes E; Sandzen J; Schatteman P; Vigmostad M; Olsson M; Ghysel C; Sautois B; De Roock W; Van Bruwaene S; Anden M; Verbiene I; De Maeseneer D; Everaert E; Darras J; Aksnessether BY; Luyten D; Strijbos M; Mortezavi A; Oldenburg J; Ost P; Eklund M; Gronberg H; Lindberg J
Article: JCO PRECISION ONCOLOGY. 2024;8:e2400209
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients
Holmsten K; Sjodahl G; Abrahamsson J; Bernardo C; Eriksson P; Hoglund M; Liedberg F; Ullen A
Article: BJU INTERNATIONAL. 2024;134(2):229-238
Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations
Holmberg L; Skogmar S; Garmo H; Hagberg O; Haggstrom C; Gardmark T; Strock V; Aljabery F; Jahnson S; Hosseini A; Jerlstrom T; Sherif A; Soderkvist K; Ullen A; Malmstrom P-U; Liedberg F
Article: RADIATION ONCOLOGY. 2024;19(1):74
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience
Svedman FC; Holmsten K; Jawdat F; Hailom W; Alm D; Grozman V; Ullen A
Article: EUROPEAN UROLOGY. 2024;85(2):154-163
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Sridhar SS; Powles T; Duran MAC; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullen A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Visa fler

Alla övriga publikationer

Review: JOURNAL OF INTERNAL MEDICINE. 2026;299(5):538-569
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field
Bjorkstrom K; Matikas A; Svedman FC; Bjorgvinsson E; Zupancic M; Villabona L; Eriksson H; Skribek M; Fernebro J; Lindskog M; Frodin J-E; Ullen A; Ekman S; Helgadottir H
Corrigendum: NATURE MEDICINE. 2024;30(11):3381
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)
De Laere B; Crippa A; Discacciati A; Larsson B; Persson M; Johansson S; D'hondt S; Bergstrom R; Chellappa V; Mayrhofer M; Banijamali M; Kotsalaynen A; Schelstraete C; Vanwelkenhuyzen JP; Hjaelm-Eriksson M; Pettersson L; Ullen A; Lumen N; Enblad G; Karlsson CT; Jaenes E; Sandzen J; Schatteman P; Vigmostad MN; Olsson M; Ghysel C; Sautois B; De Roock W; Van Bruwaene S; Anden M; Verbiene I; De Maeseneer D; Everaert E; Darras J; Aksnessether BY; Luyten D; Strijbos M; Mortezavi A; Oldenburg J; Ost P; Eklund M; Gronberg H; Lindberg J
Letter: SCANDINAVIAN JOURNAL OF UROLOGY. 2023;58(1):20
Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019'
Karttunen E; Oldenburg J; Thoresen S; Ullen A
Editorial: CANCERS. 2023;15(3):559
Optimal Systemic Treatment of Advanced Bladder Cancer Calls for a Multidisciplinary Approach
Pappot H; Ullen A
Letter: ACTA ONCOLOGICA. 2022;61(12):1515-1516
The optimal neoadjuvant chemotherapy regime for muscle-invasive bladder cancer: still an open question?
Carus A; Holmsten K; Pappot H; Ullen A
Letter: EUROPEAN UROLOGY. 2022;81(4):e92-e93
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka N-A; Hoglund M; Ullen A; Liedberg F
Editorial: CANCERS. 2020;12(12):E3607-3607
Optimal Systemic Treatment of Advanced Bladder Cancer - A Moving Target
Pappot H; Ullen A
Study protocol: TRIALS. 2020;21(1):579
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
Crippa A; De Laere B; Discacciati A; Larsson B; Connor JT; Gabriel EE; Thellenberg C; Janes E; Enblad G; Ullen A; Hjalm-Eriksson M; Oldenburg J; Ost P; Lindberg J; Eklund M; Gronberg H
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2019;140:80-87
Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series
Bamias A; Hegele A; Medioni J; Castellano D; Doni L; Passalacqua R; Zagouri F; Tzannis K; Hussain S; Ullen A
Editorial: ACTA ONCOLOGICA. 2019;58(7):951-952
Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer
Ullen A
Letter: JAMA ONCOLOGY. 2019;5(7):1060-1062
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
De Laere B; Rajan P; Gronberg H; Dirix L; Lindberg J; Mayrhofer M; Whitington T; van Dam P-J; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoela L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden G; Rutten A; Del Favero J; Rantalainen M; Sleijfer S; Ullen A; Yachnin J; Van Laere S; De laere L; Develter T; Vantieghem S; Herman S; Coifs G; Lamotte V; Boumans A; Baitar A; Haeck R; Wallays G
Letter: EUROPEAN UROLOGY. 2015;68(4):742-743
A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Prior to Radical Cystectomy: Induction Versus Neoadjuvant Chemotherapy
Liedberg F; Gudjonsson S; Kollberg P; Ullen A
Editorial: ACTA ONCOLOGICA. 2011;50:137-140
Management of advanced prostate cancer - new drugs
Ullen A; Shah C-H; Kirkali Z
Review: TUMOR BIOLOGY. 2008;29(5):311-322
Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer
Rosenblatt R; Jonmarker S; Lewensohn R; Egevad L; Sherif A; Kalkner KM; Nilsson S; Valdman A; Ullen A
Letter: ACTA ONCOLOGICA. 2007;46(6):862-863
Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer
Kalkner KM; Ullen A; Wersall P; Cohn-Cedermark G
Published conference paper: CANCER. 2002;94(4 Suppl):1314-1319
The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody.
Johansson A; Eriksson D; Ullén A; Löfroth P-O; Johansson L; Riklund-Ahlström K; Stigbrand T
Published conference paper: CANCER. 2002;94(4 Suppl):1306-1313
Idiotypic-anti-idiotypic complexes and their in vivo metabolism.
Johansson A; Erlandsson A; Eriksson D; Ullén A; Holm P; Sundström BE; Roux KH; Stigbrand T
Published conference paper: CLINICAL CANCER RESEARCH. 1999;5(10 Suppl):3073s-3078s
Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting.
Sandström P; Johansson A; Ullén A; Rathsman S; Riklund-Ahlström K; Stigbrand T
Published conference paper: ACTA ONCOLOGICA. 1999;38(3):329-334
Stability and immunoreactivity of the monoclonal anticytokeratin antibody TS1 after different degrees of iodination.
Johansson A; Sandström P; Ullén A; Erlandsson A; Sundström B; Ahlström KR; Johansson L; Hietala SO; Stigbrand T
Published conference paper: CANCER. 1997;80(12 Suppl):2689-2698
Experimental radioimmunotargeting combining nonlabeled, iodine-125-labeled, and anti-idiotypic anticytokeratin monoclonal antibodies: a dosimetric evaluation.
Rossi Norrlund R; Ullén A; Sandström P; Holback D; Johansson L; Stigbrand T; Hietala SO; Riklund Ahlström K
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI